New animal research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), reveals ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Scientists may have identified a way to naturally regulate blood sugar levels and sugar cravings in a similar fashion to ...

New research published in the American Journal of Health-System Pharmacy suggests a possible link between the GLP-1 drug ...

The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular ...